Condition: Liver Malignant Tumors · Sponsor: National Cancer Centre, Singapore
The HALT study aims to evaluate histotripsy in an Asian population for both primary (HCC, CCA) and secondary liver malignancies with liver-limited or oligoprogressive disease. In addition to safety and local control, the study incorporates translational endpoints including immune profiling (PBMCs, cytokines), microbiome shifts, and optional tumour biopsies. This trial will provide critical data on the feasibility, tolerability, and biological impact of histotripsy in a region with the highest burden of liver cancer.
This description comes directly from the study's public registry record.
Prof Brian Goh, MBBS, MMed, MSc, FRCSEd, FAMS · +65 63265440 · brian.goh@singhealth.com.sg
Sandra Hsing · sandra.hsing.san@nccs.com.sg
Always discuss trial participation with your own doctor first.
| National University Hospital | Singapore, Singapore | Not Yet Recruiting |
| National Cancer Centre Singapore | Singapore, Singapore | Recruiting |
| Singapore General Hospital | Singapore, Singapore | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07428356